UVEAL MELANOMA

This study tests a drug called tebentafusp in people with a specific genetic type (HLA-A*0201) who have metastatic uveal melanoma, a rare eye cancer that has spread and has not been treated yet. The drug aims to help the immune system attack cancer cells. Researchers will also us…

This study tests two drugs, olaparib and pembrolizumab, together in people with advanced uveal melanoma, a rare eye cancer that has spread. The goal is to see if the combination can shrink tumors or slow the cancer's growth. About 37 adults will take part in this phase 2 trial.

This early-phase study tests a new drug called NN3201, designed to find and attack cancer cells that have a specific protein called c-Kit. The trial includes people with advanced or spreading cancers like gastrointestinal stromal tumors (GIST), small-cell lung cancer, and others.…

This study tests whether the drug tebentafusp can prevent uveal melanoma (a rare eye cancer) from returning in patients at high risk of recurrence after standard treatment. About 290 adults with a specific genetic type (HLA-A*02:01) will be randomly assigned to receive tebentafus…

This early-phase trial tests a treatment made from your own immune cells (called tumor-infiltrating lymphocytes, or TILs) for advanced uveal melanoma, undifferentiated pleomorphic sarcoma, or dedifferentiated liposarcoma. About 30 participants will have their tumor removed, have …

This study tests a drug called darovasertib given before standard surgery for people with a rare eye cancer called uveal melanoma that hasn't spread. The goal is to see if the drug can prevent vision loss and help patients keep their eye instead of needing it removed. About 520 a…

This early-phase trial tests a new treatment for people with advanced melanoma or other solid tumors that have spread. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The goal is to find a safe dose and see if t…

This study tests a new drug called belzupacap sarotalocan (AU-011) for people with a rare eye cancer (choroidal melanoma) or suspicious spots that could turn into cancer. The drug is activated by a laser to target and destroy cancer cells. About 100 participants will receive eith…

This study looks at how often a specific gene change (BAP1 mutation) occurs in people with certain cancers like eye melanoma, skin melanoma, kidney cancer, and others. Researchers will study 500 patients and their family members to understand cancer patterns and risk factors. The…

This study follows 700 people with uveal melanoma (a rare eye cancer) who are at high risk of the cancer spreading to the liver. Researchers will use blood tests to look for early signs of liver metastases and tailor follow-up care to each person's risk. The goal is to improve ea…

This study looks at how the liver's immune system responds to a chemotherapy drug called melphalan, given directly to the liver through a special procedure. Ten adults with eye melanoma that has spread to the liver will have small tumor samples taken before and after treatment to…

This study tracks how choroidal melanoma and its treatment affect patients' quality of life. About 15 people already in a larger Phase 3 trial will answer questionnaires about their well-being over two years. No new drugs or procedures are tested—only information is collected.

This study looks for new genes that might cause a hereditary risk for uveal melanoma, a rare eye cancer. Only 20% of family-linked cases are explained by known genes, so researchers will analyze DNA from 50 patients to find unknown ones. The goal is to improve screening and surve…